Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
69.61 ^USD	-1.58%		+10.23%	-14.07%

25/06	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	CI
24/06	Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	MT

Gilead withdraws use of Zydelig to treat two types of cancer

January 15, 2022 at 03:30 am IST

Jan 14 (Reuters) - Gilead Sciences Inc has notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia. (Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)

Latest news about Gilead Sciences, Inc.

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	25/06	CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	24/06	MT
Tech overload on Wall Street	21/06
Wall Street set for muted open as investors await business survey data	21/06	RE
Nvidia Slide Stifles US Equity Futures Pre-Bell	21/06	MT
Top Premarket Gainers	21/06	MT
Wall Street futures edge lower ahead of business survey data	21/06	RE
Equity Markets Close Mixed as Investors Weigh Economic Data	21/06	MT
Equity Markets Close Mixed After Macro Data	21/06	MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup	21/06	DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data	21/06	MT
Sector Update: Health Care Stocks Higher Late Afternoon	21/06	MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon	20/06	MT
Equity Markets Mixed as Traders Weigh Macro Data	20/06	MT
Sliding Technology Stocks Push S&P 500, Nasdaq Composite Lower	20/06	MT
Sector Update: Health Care	20/06	MT
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump	20/06	MT
US Benchmark Stock Indexes Mixed in Midday Trading	20/06	MT
Gilead Sciences' Lenacapavir Shows 100% Efficacy, Superiority to Truvada For HIV Prevention	20/06	MT
Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial	20/06	DJ
Gilead's long-acting HIV drug superior to daily pill Truvada in study	20/06	RE
Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial	20/06	CI
Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.	17/06	CI
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	15/06	DJ
EU regulator mandates label updates on CAR-T cancer therapies	14/06	RE

Chart Gilead Sciences, Inc.

Duration

Period

More charts

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

69.61 USD

Average target price

82.97 USD

Spread / Average Target

+19.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GILEAD SCIENCES, INC.	-14.07%	8.67TCr
ELI LILLY AND COMPANY	+55.19%	81TCr
NOVO NORDISK A/S	+46.05%	65TCr
JOHNSON & JOHNSON	-6.09%	35TCr
MERCK & CO., INC.	+21.92%	34TCr
ASTRAZENECA PLC	+19.65%	25TCr
ROCHE HOLDING AG	+3.89%	23TCr
NOVARTIS AG	+13.99%	22TCr
AMGEN INC.	+10.86%	17TCr
PFIZER, INC.	-2.78%	16TCr

Other Pharmaceuticals

Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Gilead withdraws use of Zydelig to treat two types of cancer

EPS Revisions